Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

Jean Addington¹, Amy Shalev¹, Lu Liu¹, Cari Jahraus¹, Monica Chu¹, Emily Farina², Paolo Fusar Poli^{3

4}, Patricia J Marcy⁵, Angela R Nunez^{2

6}, Monica E Calkins⁷, Luis Alameda^{3

8

9}, Celso Arango¹⁰, Owen Borders¹¹, Sylvain Bouix¹², Nicholas J K Breitborde¹³, Matthew R Broome^{14

15}, Kristin S Cadenhead¹⁶, Ricardo E Carrion^{5

17

18}, Rolando I Castillo-Passi^{19

20}, Eric Yu Hai Chen²¹, Jimmy Choi²², Michael J Coleman¹¹, Philippe Conus²³, Cheryl M Corcoran²⁴, Covadonga M Diaz-Caneja¹⁰, Lauren M Ellman²⁵, Pablo A Gaspar¹⁹, Carla Gerber^{26

27}, Louise Birkedal Glenthøj^{28

29}, Leslie E Horton³⁰, Christy Lai Ming Hui²¹, Joseph Kambeitz³¹, Lana Kambeitz-Ilankovic^{31

32}, Tina Kapur³³, Sinead Kelly¹¹, Melissa J Kerr³⁴, Matcheri S Keshavan³⁵, Minah Kim^{36

37}, Sung-Wan Kim^{38

39}, Nikolaos Koutsouleris^{3

40

41}, Jun Soo Kwon^{37

42}, Kerstin Langbein⁴³, Kathryn E Lewandowski^{44

45}, Daniel Mamah⁴⁶, Daniel H Mathalon^{47

48}, Vijay A Mittal⁴⁹, Catalina Mourgues², Merete Nordentoft^{28

50}, Ofer Pasternak^{11

33

51}, Godfrey D Pearlson^{2

52}, Nora Penzel^{11

40

51}, Jesus Perez^{53

54}, Diana O Perkins⁵⁵, Albert R Powers 3rd^{2

6}, Jack Rogers^{14

56}, Fred W Sabb²⁶, Jason Schiffman⁵⁷, Johanna Seitz-Holland^{11

51}, Jai L Shah^{58

59}, Steven M Silverstein⁶⁰, Stefan Smesny⁴³, William S Stone⁶¹, Gregory P Strauss⁶², Judy L Thompson⁶³, Rachel Upthegrove^{14

64}, Swapna Verma^{65

66}, Jijun Wang⁶⁷, Daniel H Wolf⁷, Alison R Yung^{68

69}, Tianhong Zhang⁷⁰, Lauren Addamo^{34

71}, Kate Buccilli^{34

71}, Sophie Todd^{34

71}, Dominic Dwyer^{34

71}, Carrie E Bearden⁷², John M Kane^{73

74}, Patrick D McGorry^{34

71}, Rene S Kahn²⁴, Martha E Shenton^{51

75}, Scott W Woods²; Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby

Affiliations

¹ Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N 4Z6, Canada.
² Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, United States.
³ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, SE58AF, United Kingdom.
⁴ Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
⁵ Northwell, Glen Oaks, NY 11004, United States.
⁶ Connecticut Mental Health Center, New Haven, CT 06519, United States.
⁷ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19063, United States.
⁸ National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London, SE58AZ, United Kingdom.
⁹ Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne University Hospital (CHUV), 1003 Lausanne, Switzerland.
¹⁰ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, 28009 Madrid, Spain.
¹¹ Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
¹² Department of Software Engineering and Information Technology, École de Technologie Supérieure, Montréal, QC, H3C 1K3, Canada.
¹³ Department of Psychiatry and Behavioral Health, Early Psychosis Intervention Center (EPICENTER), College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
¹⁴ Institute for Mental Health, University of Birmingham, Birmingham, B152TT, United Kingdom.
¹⁵ Early Intervention for Psychosis Services, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B138QE, United Kingdom.
¹⁶ University of California, San Diego, La Jolla, CA 92104, United States.
¹⁷ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, United States.
¹⁸ Institute of Behavioral Science, Feinstein Institutes of Medical Research, Manhasset, NY 11030, United States.
¹⁹ Department of Psychiatry, University of Chile, 8330111 Santiago, Chile.
²⁰ Department of Neurology and Psychiatry, Clínica Alemana - Universidad del Desarrollo, 7610658 Santiago, Chile.
²¹ Department of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
²² Olin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health Network, Hartford, CT 06106, United States.
²³ General Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, 1003 Lausanne, Switzerland.
²⁴ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
²⁵ Department of Psychology & Neuroscience, Temple University, Philadelphia, PA 19122-6085, United States.
²⁶ Prevention Science Institute, University of Oregon, Eugene, OR 97401, United States.
²⁷ Oregon Research Institute, Springfield, OR 97477, United States.
²⁸ VIRTU Research Group, Mental Health Copenhagen, University of Copenhagen, 2900 Copenhagen, Denmark.
²⁹ Department of Psychology, University of Copenhagen, 1353 Copenhagen, Denmark.
³⁰ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
³¹ Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
³² Faculty of Psychology and Educational Sciences, Department of Psychology, Ludwig-Maximilian-University, 80802 Munich, Germany.
³³ Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
³⁴ Orygen, Parkville, Victoria, 3052, Australia.
³⁵ Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, United States.
³⁶ Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03082, South Korea.
³⁷ Department of Psychiatry, Seoul National University College of Medicine, Seoul 03080, South Korea.
³⁸ Department of Psychiatry, Chonnam National University Medical School, Gwangju 61469, South Korea.
³⁹ Mindlink, Gwangju Bukgu Mental Health Center, Gwangju 61005, South Korea.
⁴⁰ Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, 80336 Munich, Germany.
⁴¹ Max Planck Institute of Psychiatry, 80804 Munich, Germany.
⁴² Department of Psychiatry, Hanyang University Hospital, Seoul 04763, South Korea.
⁴³ Department of Psychiatry and Psychotherapy, Jena University Hospital, 07743 Jena, Germany.
⁴⁴ Psychotic Disorders Division, McLean Hospital, Belmont, MA 02478, United States.
⁴⁵ Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.
⁴⁶ Department of Psychiatry, Washington University Medical School, St. Louis, MO 63110, United States.
⁴⁷ Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94121, United States.
⁴⁸ Mental Health Service 116D, Veterans Affairs San Francisco Health Care System, San Francisco, CA 94121, United States.
⁴⁹ Department of Psychology, Northwestern University, Evanston, IL 60201, United States.
⁵⁰ Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
⁵¹ Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, United States.
⁵² Olin Neuropsychiatry Research Center, Hartford Hospital, Hartford, CT 06106, United States.
⁵³ CAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, Cambridgeshire, CB4 1PX, United Kingdom.
⁵⁴ Department of Medicine, Institute of Biomedical Research (IBSAL), Universidad de Salamanca, 37007 Salamanca, Spain.
⁵⁵ Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
⁵⁶ Centre for Human Brain Health, University of Birmingham, Birmingham, B152TT United Kingdom.
⁵⁷ Department of Psychological Science, University of California, Irvine, Irvine, CA 92697-7085, United States.
⁵⁸ Douglas Research Centre, Montreal, QC, H4H 1R3 Canada.
⁵⁹ Department of Psychiatry, McGill University, Montreal, QC H3A 1A1, Canada.
⁶⁰ Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶¹ Department of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA 02115, United States.
⁶² Department of Psychology, University of Georgia, Athens, GA 30602, United States.
⁶³ Departments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶⁴ Department of Psychiatry, University of Oxford, Oxford, OX37JX, United Kingdom.
⁶⁵ Institute of Mental Health, Singapore 539747, Singapore.
⁶⁶ Duke-NUS Medical School, Singapore 169857, Singapore.
⁶⁷ Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
⁶⁸ Institute of Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, Victoria, 3220, Australia.
⁶⁹ School of Health Sciences,University of Manchester, Manchester, M139PL, United Kingdom.
⁷⁰ Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
⁷¹ Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, 3052 Australia.
⁷² Departments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior; University of California, Los Angeles, Los Angeles, CA 90095, United States.
⁷³ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY 11549, United States.
⁷⁴ Feinstein Institute for Medical Research, Manhasset, NY 11030, United States.
⁷⁵ Department of Psychiatry and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.

PMID: 40861306
PMCID: PMC12377801
DOI: 10.1093/schizbullopen/sgaf013

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

Jean Addington et al. Schizophr Bull Open. 2025.

. 2025 Aug 25;6(1):sgaf013.

doi: 10.1093/schizbullopen/sgaf013. eCollection 2025 Jan.

Authors

Affiliations

¹ Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N 4Z6, Canada.
² Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, United States.
³ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, SE58AF, United Kingdom.
⁴ Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
⁵ Northwell, Glen Oaks, NY 11004, United States.
⁶ Connecticut Mental Health Center, New Haven, CT 06519, United States.
⁷ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19063, United States.
⁸ National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London, SE58AZ, United Kingdom.
⁹ Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne University Hospital (CHUV), 1003 Lausanne, Switzerland.
¹⁰ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, 28009 Madrid, Spain.
¹¹ Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
¹² Department of Software Engineering and Information Technology, École de Technologie Supérieure, Montréal, QC, H3C 1K3, Canada.
¹³ Department of Psychiatry and Behavioral Health, Early Psychosis Intervention Center (EPICENTER), College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
¹⁴ Institute for Mental Health, University of Birmingham, Birmingham, B152TT, United Kingdom.
¹⁵ Early Intervention for Psychosis Services, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B138QE, United Kingdom.
¹⁶ University of California, San Diego, La Jolla, CA 92104, United States.
¹⁷ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, United States.
¹⁸ Institute of Behavioral Science, Feinstein Institutes of Medical Research, Manhasset, NY 11030, United States.
¹⁹ Department of Psychiatry, University of Chile, 8330111 Santiago, Chile.
²⁰ Department of Neurology and Psychiatry, Clínica Alemana - Universidad del Desarrollo, 7610658 Santiago, Chile.
²¹ Department of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
²² Olin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health Network, Hartford, CT 06106, United States.
²³ General Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, 1003 Lausanne, Switzerland.
²⁴ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
²⁵ Department of Psychology & Neuroscience, Temple University, Philadelphia, PA 19122-6085, United States.
²⁶ Prevention Science Institute, University of Oregon, Eugene, OR 97401, United States.
²⁷ Oregon Research Institute, Springfield, OR 97477, United States.
²⁸ VIRTU Research Group, Mental Health Copenhagen, University of Copenhagen, 2900 Copenhagen, Denmark.
²⁹ Department of Psychology, University of Copenhagen, 1353 Copenhagen, Denmark.
³⁰ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
³¹ Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
³² Faculty of Psychology and Educational Sciences, Department of Psychology, Ludwig-Maximilian-University, 80802 Munich, Germany.
³³ Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
³⁴ Orygen, Parkville, Victoria, 3052, Australia.
³⁵ Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, United States.
³⁶ Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03082, South Korea.
³⁷ Department of Psychiatry, Seoul National University College of Medicine, Seoul 03080, South Korea.
³⁸ Department of Psychiatry, Chonnam National University Medical School, Gwangju 61469, South Korea.
³⁹ Mindlink, Gwangju Bukgu Mental Health Center, Gwangju 61005, South Korea.
⁴⁰ Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, 80336 Munich, Germany.
⁴¹ Max Planck Institute of Psychiatry, 80804 Munich, Germany.
⁴² Department of Psychiatry, Hanyang University Hospital, Seoul 04763, South Korea.
⁴³ Department of Psychiatry and Psychotherapy, Jena University Hospital, 07743 Jena, Germany.
⁴⁴ Psychotic Disorders Division, McLean Hospital, Belmont, MA 02478, United States.
⁴⁵ Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.
⁴⁶ Department of Psychiatry, Washington University Medical School, St. Louis, MO 63110, United States.
⁴⁷ Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94121, United States.
⁴⁸ Mental Health Service 116D, Veterans Affairs San Francisco Health Care System, San Francisco, CA 94121, United States.
⁴⁹ Department of Psychology, Northwestern University, Evanston, IL 60201, United States.
⁵⁰ Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
⁵¹ Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, United States.
⁵² Olin Neuropsychiatry Research Center, Hartford Hospital, Hartford, CT 06106, United States.
⁵³ CAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, Cambridgeshire, CB4 1PX, United Kingdom.
⁵⁴ Department of Medicine, Institute of Biomedical Research (IBSAL), Universidad de Salamanca, 37007 Salamanca, Spain.
⁵⁵ Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
⁵⁶ Centre for Human Brain Health, University of Birmingham, Birmingham, B152TT United Kingdom.
⁵⁷ Department of Psychological Science, University of California, Irvine, Irvine, CA 92697-7085, United States.
⁵⁸ Douglas Research Centre, Montreal, QC, H4H 1R3 Canada.
⁵⁹ Department of Psychiatry, McGill University, Montreal, QC H3A 1A1, Canada.
⁶⁰ Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶¹ Department of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA 02115, United States.
⁶² Department of Psychology, University of Georgia, Athens, GA 30602, United States.
⁶³ Departments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶⁴ Department of Psychiatry, University of Oxford, Oxford, OX37JX, United Kingdom.
⁶⁵ Institute of Mental Health, Singapore 539747, Singapore.
⁶⁶ Duke-NUS Medical School, Singapore 169857, Singapore.
⁶⁷ Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
⁶⁸ Institute of Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, Victoria, 3220, Australia.
⁶⁹ School of Health Sciences,University of Manchester, Manchester, M139PL, United Kingdom.
⁷⁰ Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
⁷¹ Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, 3052 Australia.
⁷² Departments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior; University of California, Los Angeles, Los Angeles, CA 90095, United States.
⁷³ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY 11549, United States.
⁷⁴ Feinstein Institute for Medical Research, Manhasset, NY 11030, United States.
⁷⁵ Department of Psychiatry and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.

PMID: 40861306
PMCID: PMC12377801
DOI: 10.1093/schizbullopen/sgaf013

Abstract

Background: This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and biomarkers in 2040 CHR and 652 CC participants.

Methods: A total of 1640 CHR and 514 CC had recruitment source data. The Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the SIPS was utilized to assess CHR criteria and severity of attenuated psychotic symptoms (APSs), and the Global Functioning: Social Scale was used for social functioning. Participants were recruited through various methods, including referrals from healthcare providers, schools, and community agencies, and self-referrals via outreach efforts and advertising.

Results: Participants were recruited from 13 different sources, with self-referral being the most common for both CHR and CC. Other notable sources included child and youth services and psychiatric hospitals and departments. Regional differences in recruitment patterns were observed across continents. Differences in age, APS, and social functioning for CHR participants were examined in the top 5 recruitment sources. Overall, self-referred individuals were typically older, with less severe APS and higher levels of functioning, whereas those from adult community mental health services had poorer functioning and more severe APS. The remaining recruitment groups fell between these 2 extremes.

Conclusion: This paper highlights the diverse recruitment sources for the AMP SCZ program. Self-referral was a significant source, particularly in North America, reflecting changing help-seeking behaviors influenced by the internet and social media. The findings underscore the importance of understanding recruitment sources to optimize future CHR research.

Keywords: AMP SCZ; ascertainment; clinical high risk; community controls; psychosis; recruitment.

PubMed Disclaimer

Conflict of interest statement

Dr. C. Arango has been a consultant to and/or has received honorarium and or grants from Acadia, Angelini, Biogen, Boehringer Ingelheim, Gideon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Shering Plough, Sumitomo Dainippon Pharma, Sunovian, and Takeda. Dr. R. Upthegrove has received speaker fees for Otsuka and consulted to Viatris and Springer Healthcare. Dr. P. Fusar Poli has received research funds or personal fees from Angelini, Boehringer Ingelheim, Lundbeck, Menarini, Otsuka, Sunovian, and Proxymm Science. Dr. S. Woods has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He owns stock in NW PharmaTech. Dr. C. Diaz-Caneja has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and honoraria or travel support from Angelini, Janssen, and Viatris. Dr. Kambeitz has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI, and Lundbeck. Patricia J. Marcy is a consultant for Otsuka and TEVA. Dr. R. S. Kahn is a consultant for Alkermes, Boehringer Ingelheim. Dr. J. Kane Consultant to or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, and Teva. Advisory Boards: Alkermes, Boehringer Ingelheim, Cerevel, Click Therapeutics, Karuna/BMS, Lundbeck, Merck, Newron, Novartis, Otsuka, Sumitomo, Teva, and Terran. Grant Support: Lundbeck, Janssen, Otsuka, and Sunovion. Shareholder interests: Cerevel (public/stock), HealthRhythms (private/stock options), Karuna/BMS (public), LB Pharmaceuticals, Inc. (private/stock options), North Shore Therapeutics (private/stock), and Vanguard Research Group (private/40% owner). All other authors report no competing interests.

Figures

**Figure 1**
Percentages of CHR and CC Participants in Each of the Recruitment Sources.

**Figure 2**
Percentages of CHR Participants from ProNET and PRESCIENT in Each of the Recruitment Sources.

See this image and copyright information in PMC

References

1. Brady LS, Larrauri CA, Committee ASS. Accelerating medicines partnership® schizophrenia (AMP® SCZ): developing tools to enable early intervention in the psychosis high risk state. World Psychiatry 2023;22:42–43. 10.1002/wps.21038 - DOI - PMC - PubMed
1. Wannan CMJ, Nelson B, Addington J et al. Accelerating medicines partnership(R) schizophrenia (AMP(R) SCZ): rationale and study design of the Largest Global Prospective Cohort Study of clinical high risk for psychosis. Schizophr Bull 2024;50:496–512. 10.1093/schbul/sbae011 - DOI - PMC - PubMed
1. Salazar De Pablo G, Radua J, Pereira J et al. Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis. JAMA Psychiatry. 2021;78:970–978. 10.1001/jamapsychiatry.2021.0830 - DOI - PMC - PubMed
1. Fusar-Poli P, Schultze-Lutter F, Cappucciati M et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull 2016;42:732–743. 10.1093/schbul/sbv162 - DOI - PMC - PubMed
1. Rietdijk J, Klaassen R, Ising H et al. Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies. Acta Psychiatr Scand 2012;126:21–30. 10.1111/j.1600-0447.2012.01839.x - DOI - PubMed

LinkOut - more resources

Full Text Sources
- PubMed Central
- Silverchair Information Systems
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

Affiliations

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Miscellaneous